Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2) - 07/06/24
, Regina M. Santella, PhD a, Bonnie R. Joubert, PhD b, Zhen Huang, MS c, Yuliya Lokhnygina, PhD c, d, Francisco Ujueta, MD, MS e, Irina Gurvich, MS a, Nancy J. LoIacono, MPH a, Filippo Ravalli, MPH a, Cynthia D. Ward, MS f, Jeffery M. Jarrett, MS f, Alfonsina De Leon Salazar, MS f, Robin Boineau, MD, MA g, Teresa L.Z. Jones, MD h, Daniel B. Mark, MD, MPH c, Jonathan D. Newman, MD, MPH i, David M. Nathan, MD j, Kevin J. Anstrom, PhD, MS k, Gervasio A. Lamas, MD e, lAbstract |
Background |
The reduction in cardiovascular disease (CVD) events with edetate disodium (EDTA) in the Trial to Assess Chelation Therapy (TACT) suggested that chelation of toxic metals might provide novel opportunities to reduce CVD in patients with diabetes. Lead and cadmium are vasculotoxic metals chelated by EDTA. We present baseline characteristics for participants in TACT2, a randomized, double-masked, placebo-controlled trial designed as a replication of the TACT trial limited to patients with diabetes.
Methods |
TACT2 enrolled 1,000 participants with diabetes and prior myocardial infarction, age 50 years or older between September 2016 and December 2020. Among 959 participants with at least one infusion, 933 had blood and/or urine metals measured at the Centers for Diseases Control and Prevention using the same methodology as in the National Health and Nutrition Examination Survey (NHANES). We compared metal levels in TACT2 to a contemporaneous subset of NHANES participants with CVD, diabetes and other inclusion criteria similar to TACT2’s participants.
Results |
At baseline, the median (interquartile range, IQR) age was 67 (60, 72) years, 27% were women, 78% reported white race, mean (SD) BMI was 32.7 (6.6) kg/m2, 4% reported type 1 diabetes, 46.8% were treated with insulin, 22.3% with GLP1-receptor agonists or SGLT-2 inhibitors, 90.2% with aspirin, warfarin or P2Y12 inhibitors, and 86.5% with statins. Blood lead was detectable in all participants; median (IQR) was 9.19 (6.30, 13.9) µg/L. Blood and urine cadmium were detectable in 97% and median (IQR) levels were 0.28 (0.18, 0.43) µg/L and 0.30 (0.18, 0.51) µg/g creatinine, respectively. Metal levels were largely similar to those in the contemporaneous NHANES subset.
Conclusions |
TACT2 participants were characterized by high use of medication to treat CVD and diabetes and similar baseline metal levels as in the general US population. TACT2 will determine whether chelation therapy reduces the occurrence of subsequent CVD events in this high-risk population.
Clinical Trials Registration |
www.clinicaltrials.gov/. Identifier: NCT02733185. NCT02733185
Le texte complet de cet article est disponible en PDF.Plan
Vol 273
P. 72-82 - juillet 2024 Retour au numéro
Article précédent
- Association between atrial fibrillation and heart failure patient reported outcomes across the ejection fraction spectrum
- Khaled Elkholey, Zain Ul Abideen Asad, Esraa Shehata, Irina Mustafina, Marat Fudim, Stavros Stavrakis
- Computerized clinical decision support to improve stroke prevention therapy in primary care management of atrial fibrillation: a cluster randomized trial
- Jafna Cox, Laura Hamilton, Lehana Thabane, Gary Foster, James MacKillop, Feng Xie, Antonio Ciaccia, Shurjeel Choudhri, Joanna Nemis-White, Ratika Parkash, IMPACT-AF Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?